Search

Displaying results 4321 - 4330 of 7059 in total
  1. Drug

    Bermekimab

    go.drugbank.com/drugs/DB14947
    Investigational

    Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).

    Synonyms: RA-18C3
  2. Drug

    CH-1504 L-isomer

    go.drugbank.com/drugs/DB19052
    Investigational

    CH-1504 L-isomer is under investigation in clinical trial NCT01116141 (A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)).

  3. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … [L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001]

  4. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel]. … [A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4.

  5. Drug

    Rezafungin

    go.drugbank.com/drugs/DB16310
    ApprovedInvestigational

    Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily. … [A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.

  6. Drug

    Nadofaragene firadenovec

    go.drugbank.com/drugs/DB17381
    ApprovedInvestigational

    Nadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFNα2b). … It is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat.

  7. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic … [L64070,L64071] It is the first regulatory T cell (Treg)-based immunotherapy approved by the FDA.[L64071]

  8. Drug

    Cresol

    go.drugbank.com/drugs/DB11143
    Approved

    Cresol is a hydroxytoluene that can be extracted naturally from coal tar or made synthetically. Pure cresol is a mixture of ortho-, meta-, and para- isomers. … At concentrations normally found in the environment however, cresols do not pose any significant risk for the general population.

  9. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    Chlormadinone acetate is a progesterone derivative first synthesized in 1961. … In 1972, the FDA withdrew its approval for the use of chlormadinone acetate in all products.

  10. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD